TMCnet News
Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1-3, 2020. The pre-recorded presentation is available for registered attendees via the Piper Sandler conference site until December 3. It will also be available on the Events and Presentations section on the Company’s website for approximately 90 days. Catalyst Biosciences will be participating in 1x1 meetings. Investors may request meetings with the management via Piper Sandler. About Catalyst Biosciences Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about candidates generated by Catalyst’s protease engineering platform having improved functionality and potency, Catalyst’s plans to enroll the first patient in a Phase 3 open-label trial of MarzAA and the Company’s collaboration with Biogen for the development and commercialization of pegylated CB 2782 Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of COVID-19 and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of neutralizing antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst’s agreement, competition and other risks described in the “Risk Factors” section of the Company’s quarterly report filed with the Securities and Exchange Commission on November 5, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law. Contact: Ana Kapor |